Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T cells followed by allo-HSCT for relapsed/refractory ALL
ChiCTR-OOC-16008448Phase 2Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Apr 2016
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19 CAR-T cells in acute lymphoblastic leukemia (ALL), sponsored by Xinqiao Hospital. Primary endpoint: One-year disease-free survival. Started Apr 2016; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR-OOC-16008448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OOC-16008448.